Kronenberg Florian, Bedlington Nicola, Ademi Zanfina, Geantă Marius, Silberzahn Tobias, Rijken Marc, Kaal Aedan, Harada-Shiba Mariko, Chen Zhenyue, Thanassoulis George, Eliasen Bogi, Eiselé Jean-Luc, Wiegman Albert, Ballantyne Christie M, Broome Emma, Calabrò Michele, Corral Pablo, Dol Annelies, Donato Leslie J, Evans Elsie, Funabashi Sayaka, Gouni-Berthold Ioanna, Ibarluzea Iñaki Gutierrez, Johnson Neil, Lane Joanna, Mora Samia, Nordestgaard Børge G, Pećin Ivan, Kaal-Poppelaars Renate, Langlois Michel R, Ray Kausik K, Rodenbach Arthur, Santos Raul D, Stroes Erik S G, Tada Hayato, Vrablík Michal, Winokur Michelle, Yoshida Masayuki, Nicholls Stephen J, Daccord Magdalena
Institute of Genetic Epidemiology, Medical University of Innsbruck, Innsbruck, Austria; Lp(a) International Task Force, FH Europe Foundation, Amsterdam, Netherlands.
Lp(a) International Task Force, FH Europe Foundation, Amsterdam, Netherlands.
Atherosclerosis. 2025 Jul;406:119218. doi: 10.1016/j.atherosclerosis.2025.119218. Epub 2025 May 5.
There is striking evidence that a high lipoprotein(a) [Lp(a)] concentration is a strong, independent, and causal cardiovascular risk factor. However, Lp(a) testing rates are very low (1 %-2 %) despite the fact that 1 in 5 individuals have elevated Lp(a) concentrations. The Brussels International Declaration on Lp(a) Testing and Management was co-created by the Lp(a) International Task Force and global leaders at the Lp(a) Global Summit, held in Brussels, Belgium, on March 24-25, 2025. The event, organized by FH Europe Foundation, brought together scientific experts, people with the lived experience of elevated Lp(a) and policy makers from the European Institutions and World Health Organization. The World Heart Federation, Global Heart Hub, and European Alliance for Cardiovascular Health and scientific organizations such as European Atherosclerosis Society, and International Atherosclerosis Society were formal partners. The Summit was hosted by a Member of the European Parliament, Romana Jerković, and held under the patronage of the Polish presidency of the Council of the European Union. The Declaration calls for 1) integration of Lp(a) testing and management into Global, European and National Cardiovascular Health Plans; 2) appropriate investment, policy and programmes in targeting Lp(a) testing and management based on a recent study demonstrating the substantial overall cost-saving to health systems across the globe; 3) political commitment to mandate systematic Lp(a) testing at least once during a person's lifetime, ideally at an early age, with full reimbursement; 4) incorporation of Lp(a) test results in the context of a person's cardiovascular risk assessment, with development of personalised cardiovascular health roadmaps as needed, without fear of dredit aiscrimination; 5) investment in public and healthcare professional education to increase awareness of Lp(a) and its impact on cardiovascular health.
有显著证据表明，高脂蛋白(a)[Lp(a)]浓度是一个强大、独立且具有因果关系的心血管危险因素。然而，尽管五分之一的个体Lp(a)浓度升高，但Lp(a)检测率却非常低(1%-2%)。《布鲁塞尔Lp(a)检测与管理国际宣言》由Lp(a)国际特别工作组与2025年3月24日至25日在比利时布鲁塞尔举行的Lp(a)全球峰会的全球领导人共同制定。该活动由FH欧洲基金会组织，汇聚了科学专家、有Lp(a)升高生活经历的人以及来自欧洲机构和世界卫生组织的政策制定者。世界心脏联盟、全球心脏中心、欧洲心血管健康联盟以及欧洲动脉粥样硬化学会和国际动脉粥样硬化学会等科学组织是正式合作伙伴。峰会由欧洲议会议员罗曼娜·耶尔科维奇主持，在欧盟理事会轮值主席国波兰的赞助下举行。该宣言呼吁：1) 将Lp(a)检测与管理纳入全球、欧洲和国家心血管健康计划；2) 根据最近一项表明可为全球卫生系统大幅节省总体成本的研究，在针对Lp(a)检测与管理方面进行适当投资、制定政策和方案；3) 做出政治承诺，规定在一个人的一生中至少进行一次系统性Lp(a)检测，最好在早年进行，并全额报销费用；4) 将Lp(a)检测结果纳入个人心血管风险评估中，并根据需要制定个性化的心血管健康路线图，而不必担心信用歧视；5) 投资于公众和医疗保健专业人员教育，以提高对Lp(a)及其对心血管健康影响的认识。
